HNGE
NEUTRAL
$45.03
Live
Hinge Health, Inc. · NYSE
Target $57.53
(+27.8%)
$30.08
52W Range
$62.18
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 28, 2026
Market cap
$3.55B
P/E
N/A
ROE
-132.9%
Profit margin
-89.9%
Debt/Equity
0.02
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
HNGE presents a stark contrast between operational growth and financial health, anchored by a weak Piotroski F-Score of 2/9. While the company exhibits strong top-line revenue growth (45.6%) and impressive gross margins (79.83%), it suffers from severe net profitability issues and a highly inflated Price-to-Book ratio of 19.95. The bullish analyst consensus is heavily contradicted by aggressive insider selling totaling $35.15M. Overall, the company is in a high-growth phase but lacks the fundamental stability required for a bullish rating.
Key Strengths
Strong YoY revenue growth of 45.60%
Excellent gross margins at 79.83%
Very low leverage with a Debt/Equity ratio of 0.02
Consistent earnings beats (3 out of last 4 quarters)
Positive operating margin (15.96%) suggesting a viable core business model
Key Risks
Critically low Piotroski F-Score (2/9) indicating weak financial health
Severe net profit margin of -89.86%
Extreme valuation premium with a Price/Book ratio of 19.95
Heavy insider liquidation ($35.15M sold, 0 bought)
Negative ROE (-132.86%) and ROA (-48.16%)
AI Fair Value Estimate
Based on comprehensive analysis
$42.5
-5.6% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
30
Weak
20
75
30
25
0
AI Verdict
Speculative Growth
Key drivers: Revenue Growth, Gross Margins, Insider Selling, Piotroski F-Score
Confidence
85%
Value
20/100
Trades at a massive premium to book value; valuation is driven by future growth expectations rather than current assets.
Positives
- Forward P/E of 19.40 is reasonable for the sector
Watchpoints
- P/B ratio of 19.95 is excessive
- No Graham Number available due to lack of earnings/book value stability
Future
75/100
Growth metrics are the primary driver of the current stock price.
Positives
- 45.6% Revenue growth
- Strong analyst target price of $57.53
- Positive Q/Q earnings growth trend
Watchpoints
- High burn rate implied by net profit margins
Past
30/100
Historical performance shows a company struggling to convert revenue into net profit.
Positives
- Strong earnings surprise track record
Watchpoints
- Consistent negative ROE and ROA
- Poor earnings growth YoY (-80.8%)
Health
25/100
While not at immediate risk of bankruptcy due to low debt, the operational health is weak.
Positives
- Low Debt/Equity (0.02)
- Current Ratio (1.47) provides short-term liquidity
Watchpoints
- Piotroski F-Score of 2/9 is a major red flag for fundamental health
Dividend
0/100
Company is in a growth phase and does not return capital to shareholders.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$45.03
Analyst Target
$57.53
Upside/Downside
+27.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HNGE and closest competitors.
Updated 2026-04-27
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HNGE
Hinge Health, Inc.
Primary
|
+19.9% | +19.9% | +19.9% | -9.7% | +24.2% | +2.5% |
|
ACAD
ACADIA Pharmaceuticals Inc.
Peer
|
-31.3% | +1.1% | +22.8% | -12.7% | -8.3% | -7.0% |
|
ADMA
ADMA Biologics, Inc.
Peer
|
+604.6% | +370.5% | -15.4% | -6.0% | -6.9% | -1.6% |
|
TLX
Telix Pharmaceuticals Limited
Peer
|
-29.2% | -29.2% | -33.8% | -0.6% | +22.6% | -4.5% |
|
LIVN
LivaNova PLC
Peer
|
-22.5% | +45.9% | +83.9% | +23.9% | +0.8% | -1.6% |
HNG
Hinge Health, Inc.
Primary
5Y
+19.9%
3Y
+19.9%
1Y
+19.9%
6M
-9.7%
1M
+24.2%
1W
+2.5%
ACA
ACADIA Pharmaceuticals Inc.
Peer
5Y
-31.3%
3Y
+1.1%
1Y
+22.8%
6M
-12.7%
1M
-8.3%
1W
-7.0%
ADM
ADMA Biologics, Inc.
Peer
5Y
+604.6%
3Y
+370.5%
1Y
-15.4%
6M
-6.0%
1M
-6.9%
1W
-1.6%
TLX
Telix Pharmaceuticals Limited
Peer
5Y
-29.2%
3Y
-29.2%
1Y
-33.8%
6M
-0.6%
1M
+22.6%
1W
-4.5%
LIV
LivaNova PLC
Peer
5Y
-22.5%
3Y
+45.9%
1Y
+83.9%
6M
+23.9%
1M
+0.8%
1W
-1.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
19.4
PEG Ratio
N/A
P/B Ratio
19.95
P/S Ratio
6.03
EV/Revenue
5.77
EV/EBITDA
-6.23
Market Cap
$3.55B
Profitability
Profit margins and return metrics
Profit Margin
-89.86%
Operating Margin
15.96%
Gross Margin
79.83%
ROE
-132.86%
ROA
-48.16%
Growth
Revenue and earnings growth rates
Revenue Growth
+45.6%
Earnings Growth
-80.8%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+18.4%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.02
Low debt
Current Ratio
1.47
Good
Quick Ratio
1.19
Good
Cash/Share
$4.62
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
84.4%
Op. Margin
16.0%
Net Margin
18.8%
Total Assets
$0.7B
Liabilities
$0.4B
Equity
$0.4B
Debt/Equity
0.97x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
96%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-10
$0.49
+15.2% surprise
2025-11-04
$-0.02
+90.5% surprise
2025-08-05
$0.7
+710.6% surprise
Healthcare Sector Comparison
Comparing HNGE against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-132.86%
This Stock
vs
-88.14%
Sector Avg
+50.7%
(Excellent)
Profit Margin
-89.86%
This Stock
vs
-16.28%
Sector Avg
+452.0%
(Superior)
Debt to Equity
0.02
This Stock
vs
2.66
Sector Avg
-99.2%
(Less Debt)
Revenue Growth
45.6%
This Stock
vs
124.04%
Sector Avg
-63.2%
(Slower)
Current Ratio
1.47
This Stock
vs
4.47
Sector Avg
-67.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HNGE
Hinge Health, Inc.
|
NEUTRAL | $3.55B | - | -132.9% | -89.9% | $45.03 | |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
NEUTRAL | $3.51B | 8.96 | 39.9% | 36.5% | $20.61 | Compare |
|
ADMA
ADMA Biologics, Inc.
|
BEARISH | $3.61B | 25.25 | 35.6% | 28.8% | $15.15 | Compare |
|
TLX
Telix Pharmaceuticals Limited
|
NEUTRAL | $3.64B | - | -1.9% | -0.9% | $10.73 | Compare |
|
LIVN
LivaNova PLC
|
NEUTRAL | $3.43B | - | -19.2% | -17.5% | $62.78 | Compare |
HNGE
Hinge Health, Inc.
NEUTRAL
Mkt Cap
$3.5B
P/E
-
ROE
-132.9%
Price
$45.03
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-21 | MECKLENBURG GABRIEL M.I. | Director | Sale | 33,333 | $1,501,528 |
| 2026-04-21 | MECKLENBURG GABRIEL M.I. | Director | Stock Award | 33,333 | - |
| 2026-04-02 | SLOAT TYLER | Director | Stock Award | 68 | $2,883 |
| 2026-04-01 | MECKLENBURG GABRIEL M.I. | Director | Sale | 50,000 | $1,922,780 |
| 2026-04-01 | MECKLENBURG GABRIEL M.I. | Director | Stock Award | 50,000 | - |
| 2026-03-23 | BUDGE JAMES W. | Chief Financial Officer | Sale | 11,006 | $465,139 |
| 2026-03-23 | PURSLEY JAMES | President | Sale | 15,000 | $633,927 |
| 2026-03-16 | SLOAT TYLER | Director | Stock Award | 9,896 | - |
| 2026-03-06 | MECKLENBURG GABRIEL M.I. | Director | Sale | 166,666 | $7,552,645 |
| 2026-03-06 | MECKLENBURG GABRIEL M.I. | Director | Stock Award | 166,666 | - |
| 2026-02-23 | BUDGE JAMES W. | Chief Financial Officer | Sale | 14,763 | $580,737 |
| 2026-02-23 | PURSLEY JAMES | President | Sale | 15,000 | $589,984 |
| 2026-02-17 | PEREZ DANIEL ANTONIO | Chief Executive Officer | Gift | 7,260 | - |
| 2026-02-17 | PEREZ DANIEL ANTONIO | Chief Executive Officer | Stock Award | 7,260 | - |
| 2026-02-13 | ROBINSON ELLIOTT | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | 173,351 | $6,952,631 |
MECKLENBURG GABRIEL M.I.
Director
2026-04-21
33,333 shares
·
$1,501,528
MECKLENBURG GABRIEL M.I.
Director
2026-04-21
33,333 shares
SLOAT TYLER
Director
2026-04-02
68 shares
·
$2,883
MECKLENBURG GABRIEL M.I.
Director
2026-04-01
50,000 shares
·
$1,922,780
MECKLENBURG GABRIEL M.I.
Director
2026-04-01
50,000 shares
BUDGE JAMES W.
Chief Financial Officer
2026-03-23
11,006 shares
·
$465,139
PURSLEY JAMES
President
2026-03-23
15,000 shares
·
$633,927
SLOAT TYLER
Director
2026-03-16
9,896 shares
MECKLENBURG GABRIEL M.I.
Director
2026-03-06
166,666 shares
·
$7,552,645
MECKLENBURG GABRIEL M.I.
Director
2026-03-06
166,666 shares
BUDGE JAMES W.
Chief Financial Officer
2026-02-23
14,763 shares
·
$580,737
PURSLEY JAMES
President
2026-02-23
15,000 shares
·
$589,984
PEREZ DANIEL ANTONIO
Chief Executive Officer
2026-02-17
7,260 shares
PEREZ DANIEL ANTONIO
Chief Executive Officer
2026-02-17
7,260 shares
ROBINSON ELLIOTT
Director and Beneficial Owner of more than 10% of a Class of Security
2026-02-13
173,351 shares
·
$6,952,631
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
15 analysts
Evercore ISI Group
2026-04-08
Outperform
Outperform
RBC Capital
2026-03-11
Outperform
Outperform
Canaccord Genuity
2026-02-11
Buy
Buy
RBC Capital
2026-02-11
Outperform
Outperform
Citizens
2026-02-11
Market Outperform
Market Outperform
Evercore ISI Group
2026-02-11
Outperform
Outperform
Barclays
2026-02-11
Overweight
Overweight
Needham
2026-02-11
Buy
Buy
Freedom Capital Markets
2026-01-23
Buy
Piper Sandler
2026-01-09
Overweight
Overweight
Past News Coverage
Recent headlines mentioning HNGE from our newsroom.
Newest → oldest
No matching news yet.